Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | BRIP1 T997fs |
Gene Variant Detail | |
Relevant Treatment Approaches | Olaparib |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
BRIP1 T997fs | breast lobular carcinoma | predicted - sensitive | Olaparib | Olaparib | Case Reports/Case Series | Actionable | In a clinical case study, Lynparza (olaparib) treatment resulted in a sustained metabolic response and a decrease in the cancer antigen markers CA 27-29 and CA 15-3 after 8 months in a patient with recurrent ER/PR-positive, ERBB2 (HER2)-negative invasive lobular breast carcinoma harboring a germline BRIP1 T997fs, who remained on treatment (PMID: 36813328). | 36813328 |